Open Actively Recruiting

Randomized Controlled Trial of Standard ERP and OC-Go

About

Brief Summary

Phase II of this study will examine the efficacy of the OC-Go application via a randomized controlled trial comparing standard exposure and response prevention (ERP) treatment for pediatric obsessive compulsive disorder (OCD) to exposure/response prevention (ERP) augmented with OC-Go. A cross-over design will be implemented for these 12 sessions of treatment, in which participants that were randomized to standard ERP will receive OC-Go augmented ERP for the second half of treatment, and vice versa. Efficacy will be investigated in a sample of 32 children with OCD.

Primary Purpose
Treatment
Study Type
Interventional
Phase
N/A

Eligibility

Gender
All
Healthy Volunteers
No
Minimum Age
9 Years
Maximum Age
17 Years

Inclusion Criteria:

  • Ages 9-17 years old
  • Primary diagnosis of OCD based on diagnostic interview (ADIS)
  • CGI-Severity score > 3

Exclusion Criteria:

  • Anti-OCD medication/unstable dose (with changes expected during the study)
  • Significant and interfering comorbid psychiatric, psychosocial, neurological, or medical condition (e.g., acute suicidality, low IQ, etc.) precluding the child's ability to complete all study procedures

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
18-000739
Category
Semel Institute (Psychiatry)
Contact
KATHERINE DELGADILLO-SOTO
Location
  • UCLA Westwood
For Providers
NCT No.
NCT03601312
For detailed technical eligibility, visit ClinicalTrials.gov.